Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs -- Ignore unavailable to you. Want to Upgrade?

To: David Lawrence who wrote (270)	3/23/1998 4:55:00 PM
From: Tony J Brice	Read Replies (1) \| Respond to of 384

Related Story: RESEARCH ALERT - Watson Pharmaceutical cut NEW YORK, March 23 (Reuters) - SBC Warburg Dillon Read said on Monday it lowered its rating on shares of Watson Pharmaceuticals Inc to outperform on buy. -- Mylan Laboratories Inc (MYL - news) said it won approval from the U.S. Food and Drug Administration to manufacture and market a generic version of the hypertension drug ''Dilacor XR.'' -- Watson, which acquired the rights to the Dilacor XR brand from Rhone Poulenc Rorer in June 1997 for $190 million, is generating close to $80 million in annualized sales from the brand product and also holds roughly 75 percent of generic market, analyst Jerry Treppel said in research note. -- Dilacor is easily company's most important product. -- Treppel believes stock's upside will be limited over near-term because of lack of visibility about what company's next major growth drivers will be.